RCEL Similar Chart Price Prediction
The price of RCEL is predicted to go up 1.42%, based on the high correlation periods with NSIT. The similarity of these two price pattern on the periods is 94.37%.
RCEL
NSIT
Up: 1.42%Similarity: 94.37%
RCEL Revenue Forecast
RCEL EPS Forecast
RCEL FAQs
What is RCEL revenue forecast for next quarter？
What is RCEL eps forecast for next quarter？
RCEL Analyst's Forecast
Jason Kolbert
D. Boral Capital
Strong Buy
2025-02-20
Price Target
$25 → $22
Upside
+121.11%
D. Boral Capital lowered the firm's price target on Avita Medical to $22 from $25 and keeps a Buy rating on the shares. The CFO of Avita informed D. Boral that the company has no plans to enter the chronic wounds market for the foreseeable future. As a result, the firm removed chronic wounds from its model and adjusted its acute wounds market share assumptions to align with the company's published guidance. With limited resources, Avita is prioritizing areas where its product attributes can have the greatest impact, the analyst tells investors in a research note.
Ross Osborn
Cantor Fitzgerald
Buy
2024-12-24
Price Target
$21
Upside
+62.66%
Jason Kolbert
D. Boral Capital
Strong Buy
2024-12-24
Price Target
$25
Upside
+93.65%
